Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,203,792
  • Shares Outstanding, K 661,710
  • Annual Sales, $ 22,849 M
  • Annual Income, $ 1,979 M
  • 36-Month Beta 1.38
  • Price/Sales 5.33
  • Price/Cash Flow 11.99
  • Price/Book 7.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
175.77 +5.93%
on 05/29/18
186.74 -0.29%
on 06/15/18
+9.89 (+5.61%)
since 05/18/18
3-Month
163.31 +14.01%
on 04/02/18
186.74 -0.29%
on 06/15/18
+3.64 (+1.99%)
since 03/19/18
52-Week
163.31 +14.01%
on 04/02/18
201.23 -7.47%
on 01/29/18
+21.10 (+12.78%)
since 06/19/17

Most Recent Stories

More News
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER...

AMGN : 186.19 (+1.22%)
Health Canada approves Amgen's Repatha® (evolocumab) to reduce the risk of cardiovascular events in adults with Atherosclerotic Cardiovascular Disease

New Indication Supports Amgen's Commitment to Reduce the Risk of Recurrent Cardiovascular Events Faced by Heart Attack and Stroke Survivors

AMGN : 186.19 (+1.22%)
Teva to Discontinue a Fremanezumab Study on Cluster Headache

Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint....

ALDR : 17.80 (+3.19%)
NVS : 73.57 (-0.70%)
TEVA : 24.05 (-0.70%)
AMGN : 186.19 (+1.22%)
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus

Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.

NVS : 73.57 (-0.70%)
RHHBY : 26.5300 (+0.53%)
AMGN : 186.19 (+1.22%)
BIIB : 292.04 (+1.01%)
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA

Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial...

AGLE : 10.82 (-0.64%)
ILMN : 285.74 (-1.08%)
RHHBY : 26.5300 (+0.53%)
AMGN : 186.19 (+1.22%)
Allergan (AGN) Presents Positive Data on Glaucoma Candidate

Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

LLY : 86.82 (+0.82%)
AGN : 173.05 (+0.77%)
NVS : 73.57 (-0.70%)
AMGN : 186.19 (+1.22%)
Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication

Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.

MRK : 61.03 (+0.07%)
LLY : 86.82 (+0.82%)
AMGN : 186.19 (+1.22%)
GSK : 41.04 (-0.56%)
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer

Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.

MRK : 61.03 (+0.07%)
AMGN : 186.19 (+1.22%)
PFE : 36.22 (+0.17%)
GSK : 41.04 (-0.56%)
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

AXON : 2.90 (-15.20%)
REGN : 327.07 (+3.63%)
AMGN : 186.19 (+1.22%)
ALXN : 121.91 (+2.73%)
BIIB : 292.04 (+1.01%)
Initiating Free Research Reports on ArQule and Three Other Biotech Equities

Stock Research Monitor: AMAG, AMGN, and ARNA

ARNA : 49.58 (+1.41%)
AMAG : 22.55 (-1.96%)
AMGN : 186.19 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 188.63
1st Resistance Point 187.41
Last Price 186.19
1st Support Level 183.90
2nd Support Level 181.61

See More

52-Week High 201.23
Fibonacci 61.8% 186.74
Last Price 186.19
Fibonacci 50% 182.27
Fibonacci 38.2% 177.80
52-Week Low 163.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar